Document Details

Document Type : Article In Journal 
Document Title :
Experience of 12-month therapy with acarbose, glibenclamide, and metformin in uncontrolled Saudi Type diabetic patients
Experience of 12-month therapy with acarbose, glibenclamide, and metformin in uncontrolled Saudi Type diabetic patients
 
Document Language : English 
Abstract : We conducted this study to evaluate the effect of adding acarbose to a regimen of maximum glibenclamid and metformin combination on the glycaemic control of Saudi Type 2 diabetic patients. A total of 176 patients were included with mean age of 56 years and mean duration of diabetic of 8.7 years. There was a significant drop in the median fasting and postprandial blood glucose level and HbA, from 11.6 mmol/L,17.8 mmol/L (9.9%), to 6.9 mmol/L,10 mmol/L (7.1%), respectively (p <0.001 for all). There was no significant change in the median body mass index or serum lipids during the study periode. Gastrointestinal side-effects developed in 34% of patients but none of the patients developed any hypoglycaemic attacks. Acarbose can be combined successfully with glibenclamide and metformin for better glycaemic control in Type 2 diabetic patients. 
ISSN : 1319-1004 
Journal Name : Diabetes International 
Volume : 11 
Issue Number : 1 
Publishing Year : 2001 AH
2001 AD 
Article Type : Article 
Added Date : Monday, March 1, 2010 

Researchers

Researcher Name (Arabic)Researcher Name (English)Researcher TypeDr GradeEmail
أ.د. دعـــد أكبرAkbar, Prof. Daad ResearcherDoctorate 

Files

File NameTypeDescription
 25769.doc doc 

Back To Researches Page